Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific and investor conferences in May 2026, including Bank of America Health Care Conference (May 12), Stifel Virtual Ophthalmology Forum (May 26), ARVO (May 1–7) and Retina World Congress (May 14–17), plus the Royal College of Ophthalmologists congress (May 18–20).

Key presentations cover Phase 3 OTX-TKI SOL-1 results, TKI program updates, real-world anti-VEGF analyses, and company fireside chats. Webcasts will be available via the company investor relations Events and Presentations page, with replays archived for at least 30 days.

News Market Reaction – OCUL

+0.32%

5 alerts

+0.32% Session close to close

+9.6% Peak in 28 min

$2.16B Market Cap

0.1x Rel. Volume

In the Apr 27 session, OCUL gained 0.32%, reflecting a mild positive market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines an intensive May schedule of scientific and investor conferences, featuri...

Analysis

This announcement outlines an intensive May schedule of scientific and investor conferences, featuring Phase 3 SOL-1 results, real-world nAMD data, and multiple retina-focused symposia. In recent months, OCUL has coupled such events with incremental SOL-1 disclosures and an upcoming Investor Day, reinforcing its retina strategy. Investors may watch how these meetings refine the AXPAXLI narrative, support potential regulatory steps, and maintain engagement with key opinion leaders and institutional audiences over the coming weeks.

Key Figures

Bank of America fireside chat: 3:40 – 4:10 PM PDT Stifel fireside chat: 2:30 – 2:55 PM EDT SOL-1 trial presentation: 1:15 – 1:30 PM MDT +5 more

8 metrics

Bank of America fireside chat 3:40 – 4:10 PM PDT May 12, 2026 Bank of America Health Care Conference

Stifel fireside chat 2:30 – 2:55 PM EDT May 26, 2026 Stifel 2026 Virtual Ophthalmology Forum

SOL-1 trial presentation 1:15 – 1:30 PM MDT Phase 3 SOL-1 trial results at ARVO 2026, May 5, 2026

ARVO poster session window 8:00 – 9:45 AM MDT Vestrum database nAMD poster, May 7, 2026

IRIS Registry poster window 8:00 – 9:45 AM MDT nAMD treatment patterns poster, May 7, 2026

RWC retina talk 8:15 – 8:20 AM EDT Retina Experience Redefined at Retina World Congress, May 14, 2026

OTX-TKI data update 4:30 – 4:35 PM EDT Latest TKI data from OTX-TKI program at RWC, May 15, 2026

UK symposium slot 12:30 – 1:30 PM BST nAMD management symposium at RCOphth Congress, May 19, 2026

Historical Context

5 past events · Latest: Apr 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 22	Investor Day announcement	Positive	+3.5%	Planned June 17, 2026 Investor Day with leadership and KOL participation.
Apr 14	Inducement grants	Negative	-1.1%	Equity awards to new hires and senior executive under inducement plan.
Apr 13	Phase 3 data update	Positive	+0.8%	Additional Week 52 SOL-1 Phase 3 analyses showing unmatched durability vs aflibercept.
Apr 01	Conference presentations	Positive	-1.6%	Plan to present additional SOL-1 Phase 3 data at April scientific meetings.
Mar 09	Inducement grants	Negative	-0.7%	Stock options and RSUs granted to new non-executive employees under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Most recent OCUL news events, especially positive clinical and investor-related updates, have seen price moves generally aligned with the news tone, with one recent conference-related divergence.

Recent Company History

Over the last few months, OCUL has highlighted its retina franchise and AXPAXLI program through multiple catalysts. A Mar 9 and Apr 14 series of inducement grants coincided with mildly negative price reactions. By contrast, positive SOL-1 Phase 3 data on Apr 13 and an Apr 22 Investor Day announcement saw modest gains. Earlier April conference presentations on SOL-1 drew a small decline. Today’s May conference slate continues this pattern of active scientific and investor engagement.

Key Terms

intravitreal, hydrogel, neovascular age-related macular degeneration, phase 3, +1 more

5 terms

intravitreal medical

"Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular..."

An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.

hydrogel medical

"Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular..."

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

neovascular age-related macular degeneration medical

"...in Neovascular Age-Related Macular Degeneration: Phase 3 SOL-1 Trial Results"

A progressive eye disease in older adults where abnormal blood vessels grow beneath the central retina and leak fluid or blood, quickly damaging sharp central vision used for reading and recognizing faces. For investors, it matters because it creates ongoing demand for medical treatments, diagnostics and follow-up care, and outcomes hinge on clinical trial results, regulatory approvals and reimbursement decisions that can sharply affect the value of companies developing therapies — like a chronic market need driven by a high-impact illness.

phase 3 medical

"...Macular Degeneration: Phase 3 SOL-1 Trial Results Presentation Date/Time..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

anti-VEGF medical

"Poster Title: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes..."

Anti-VEGF describes medicines or treatments that block a protein called vascular endothelial growth factor (VEGF), which tells the body to grow new blood vessels. By shutting off that signal, these therapies can slow or stop unwanted vessel growth and leaking in diseases such as certain eye disorders and cancers. Investors watch anti-VEGF programs because they can command large markets, affect patient outcomes, and drive drug sales, royalties, and valuation like controlling a major pipeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026.

Upcoming Investor Conferences:

Bank of America Health Care Conference 2026:
Date: Tuesday, May 12, 2026
Fireside Chat: 3:40 – 4:10 PM PDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Las Vegas, NV

Stifel 2026 Virtual Ophthalmology Forum:
Date: Tuesday, May 26, 2026
Fireside Chat: 2:30 – 2:55 PM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual

A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.

Upcoming Scientific Conferences:

Eyecelerator @ ARVO 2026: May 1, 2026
Denver, CO

• Presentation: Ocular Therapeutix: Retina Experience Redefined
  
  

Presentation Date/Time: Friday, May 1, 2026, 2:18 – 2:23 PM MDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix

ARVO 2026 Annual Meeting: May 3 - 7, 2026
Denver, CO

• Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Phase 3 SOL-1 Trial Results
  
  

Presentation Date/Time: Tuesday, May 5, 2026, 1:15 – 1:30 PM MDT
Presenter: Patricio G. Schlottmann, MD

• Poster Title: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database
  
  

Session Date/Time: Thursday, May 7, 2026, 8:00 – 9:45 AM MDT
Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS

• Poster Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry
  
  

Session Date/Time: Thursday, May 7, 2026, 8:00 – 9:45 AM MDT
Presenter: Christina Y. Weng, MD, MBA

Retina World Congress (RWC) 2026: May 14 - 17, 2026
Fort Lauderdale, FL

• Presentation Title: Ocular Therapeutix: Retina Experience Redefined
  
  

Presentation Date/Time: Thursday, May 14, 2026, 8:15 – 8:20 AM EDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix

• Presentation Title: Update on Latest TKI data from the OTX-TKI program
  
  

Presentation Date/Time: Friday, May 15, 2026, 4:30 – 4:35 PM EDT
Presenter: Dilsher S. Dhoot, MD

• Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  
  

Symposium Date/Time: Friday, May 15, 2026, 7:15 – 8:15 PM EDT
Presenters: Patricio G. Schlottmann, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD

The Royal College of Ophthalmologists Annual Congress 2026: May 18 - 20, 2026
Manchester, UK

• Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  
  

Symposium Date/Time: Tuesday, May 19, 2026, 12:30 – 1:30 PM BST
Presenters: Adnan Tufail, MBBS, MD, FRCOphth; Darius M. Moshfeghi, MD; Dilsher S. Dhoot, MD

Exact medical conference presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When will Ocular Therapeutix (OCUL) present Phase 3 OTX-TKI SOL-1 results at ARVO 2026?

Ocular will present the Phase 3 OTX-TKI SOL-1 trial results on Tuesday, May 5, 2026 at 1:15 PM MDT. According to Ocular Therapeutix, the presentation covers efficacy and safety data for intravitreal axitinib hydrogel in nAMD.

How can investors watch Ocular Therapeutix (OCUL) fireside chats in May 2026?

Investors can watch live webcasts of the Bank of America (May 12) and Stifel (May 26) fireside chats via the company’s Events and Presentations investor relations webpage. According to Ocular Therapeutix, replays will be archived for at least 30 days after each presentation.

What OTX-TKI updates will Ocular Therapeutix (OCUL) present at Retina World Congress 2026?

Ocular will present an overview titled Retina Experience Redefined on May 14 and a TKI program data update on May 15, 2026. According to Ocular Therapeutix, sessions include the latest TKI data and implications for durability and disease control in nAMD.

Which Ocular Therapeutix (OCUL) speakers are scheduled for May 2026 scientific meetings?

Scheduled presenters include Pravin U. Dugel, MD; Peter K. Kaiser, MD; Patricio G. Schlottmann, MD; Andrew A. Moshfeghi, MD; and others. According to Ocular Therapeutix, presenters will cover SOL-1 results, real-world analyses, and program updates across multiple conferences.

Will Ocular Therapeutix (OCUL) present real-world anti-VEGF analyses at ARVO 2026 and when?

Yes. Real-world anti-VEGF treatment utilization and vision outcome analyses are scheduled as posters on Thursday, May 7, 2026, 8:00–9:45 AM MDT. According to Ocular Therapeutix, presenters include Andrew A. Moshfeghi and Christina Y. Weng.